NBTX Profile
Nanobiotix S.A., a clinical-stage biotechnology firm headquartered in Paris, France, is at the forefront of developing innovative treatments for cancer. The company specializes in harnessing advanced nanotechnology to enhance cancer therapies, focusing on its flagship product, NBTXR3. NBTXR3 is a unique sterile aqueous suspension of crystalline hafnium oxide nanoparticles designed to improve the effectiveness of radiation therapy in treating a range of cancers, including soft tissue sarcoma, head and neck cancers, liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
NBTXR3 works by enhancing the impact of radiation therapy at the cellular level. The hafnium oxide nanoparticles are designed to amplify the radiotherapeutic effect by increasing the dose of radiation absorbed by tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to improve clinical outcomes and provide a more targeted and effective treatment option for patients with various types of cancer. The therapy is currently undergoing clinical trials to establish its safety and efficacy across multiple cancer indications.
Nanobiotix has strategically partnered with LianBio to advance the development and commercialization of NBTXR3 in several key markets, including Greater China, South Korea, Singapore, and Thailand. This partnership is instrumental in expanding the global reach of NBTXR3 and bringing this cutting-edge technology to a broader patient population. The collaboration underscores Nanobiotix's commitment to leveraging international partnerships to accelerate the delivery of its innovative treatments to market.
Founded in 2003, Nanobiotix S.A. has built a robust portfolio of research and development activities centered on nanomedicine and oncology. The company’s efforts are directed toward pioneering novel cancer treatments that offer enhanced efficacy and improved patient outcomes. As Nanobiotix continues to advance its clinical programs and explore new therapeutic opportunities, it remains dedicated to transforming the landscape of cancer care through its innovative nanotechnology-based approaches.
|
